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Abstract The N-terminus of MDM2 proto-oncoprotein inter-
acts with p53 and down modulates p53 activity by inhibiting
transcriptional activity and promoting p53 degradation. MDMX
is structurally related to MDM2 and also binds to p53. However,
the function of MDMX has not been clarified yet. We found that
MDM2 hetero-oligomerized with MDMX through their C-
terminal RING finger domains. Yeast two-hybrid analysis
revealed that the hetero-oligomerization between MDMX and
MDM2 was more stable than the homo-oligomerization of each
protein. MDM2 has been shown to be degraded by the ubiquitin-
proteasome pathway, while MDMX was a stable protein.
Interaction of MDMX with MDM2 through the C-terminal
RING finger domains resulted in inhibiting degradation of
MDM2. These data indicate that MDMX functions as a
regulator of MDM2.
z 1999 Federation of European Biochemical Societies.
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1. Introduction
The p53 tumor suppresser gene product plays an important
role in the prevention of malignancies. The function of this
protein is lost in many cancers and sarcomas. p53 exhibits
DNA binding activity and functions as a transcription factor.
It induces the expression of a number of genes including p21/
WAF/Cip1, Bax, cyclin G, GADD45, and MDM2, which are
involved in cell cycle regulation, DNA repair and apoptosis
[1^3]. Among them, MDM2 has been suggested as being a
negative feedback regulator of p53 [4].
The MDM2 oncogene was ¢rst cloned as an ampli¢ed gene
on a murine double-minute chromosome in the 3T3DM cell
line [5]. Overexpression of MDM2 increased the tumorigenic
potential of immortalized NIH3T3 cells, demonstrating that
the MDM2 protein does possess oncogenic activity [6]. The
MDM2 gene was found to be ampli¢ed in a signi¢cant pro-
portion of human sarcoma as well as in a variety of other
tumors [7].
The gene encodes the 489 amino acid polypeptide that con-
tains a p53 binding motif at the N-terminus, an acidic region
and two putative metal binding motifs (zinc ¢nger motif and
RING ¢nger motif) [8]. The expression of MDM2 increases at
least 1 h after the induction of p53 and has been thought to
suppress the activity of p53 by masking the N-terminal trans-
activation domain of p53 [9,10]. Furthermore, recent reports
indicate that MDM2 accelerates p53 degradation and p19ARF
has been shown to regulate this process [11^14]. MDM2 C-
terminal regions are suggested to function as ubiquitin ligase
E3 for p53 [15,16], and MDM2 itself is degraded by the ubiq-
uitin-proteasome pathway [17].
MDMX, which is structurally similar to MDM2, was
cloned as a p53-binding protein [18,19]. Like MDM2,
MDMX interacts with the N-terminal region of p53 and par-
tially inhibits p53 transcriptional activity. Importantly, expres-
sion of MDMX seems to be regulated di¡erently from that of
MDM2 [18]. The level of MDMX mRNA is unchanged after
UV irradiation, in contrast to MDM2 mRNA. However, the
physiological function of MDMX is unknown.
In the present study, we screened MDM2 C-terminus-inter-
acting proteins by using a yeast two-hybrid system. We found
that the C-terminal region of MDM2 containing the RING
¢nger motif bound to the comparable region of MDMX. This
interaction is dependent on the presence of the RING ¢nger
domain and hetero-oligomerization between MDM2 and
MDMX was more stable than homo-oligomerization of
each protein. This study is the ¢rst demonstration of hetero-
oligomeric interaction between the two-related RING ¢nger
domains. Coexpression of MDMX inhibited degradation of
MDM2, suggesting that MDMX modulates ubiquitin-protea-
some dependent proteolysis of MDM2 by interacting with the
C-terminal region.
2. Materials and methods
2.1. Yeast two-hybrid assay
The cDNAs encoding the N-terminal half (1^294) and the C-termi-
nal half (294^491) of human MDM2 were cloned into a pBTM116
vector in frame with the LexA DNA-binding domain to yield pBTM-
MDM2 vectors. These vectors were transfected into yeast strain L40
as described [20]. The human thymus cDNA library in the pGAD10
vector (Clontech) was introduced into the L40 transformant bearing
pBTM-JH1 by the LiCl method. Yeast expressing interacting proteins
was identi¢ed by growth on media lacking leucine, tryptophan and
histidine, and con¢rmed by assaying for L-galactosidase activity [20].
2.2. Binding assay between MDM2 and MDMX in vitro and in vivo
Full length MDM2 cDNA was fused with N-terminal Myc epitope
tag sequence and subcloned into a mammalian expression vector
pCAGGS [20]. Full length MDMX cDNA was subcloned into
pcDNA3 with N-terminal Myc-epitope tag [20]. C-terminal truncated
MDMX (MDMXvC) was obtained by deleting the EcoRI/XbaI frag-
ment from pcDNA3-MDMX. The resulting cDNA lacked a C-termi-
nal 96 amino acid containing the RING ¢nger domain. GST-MDM2
or GST-MDMX RING ¢nger domain constructs were obtained by
the subcloning of appropriate PCR fragments into pGEX-4T vectors
(Pharmacia).
For in vitro binding assay, GST-RING ¢nger domains were pro-
duced in NM522 bacteria and puri¢ed on GSH-Sepharose in the
presence of 1 mM ZnCl2. MDM2 and MDMX or MDMXvC were
transiently expressed in 293 cells by the calcium phosphate precipita-
tion method. After 2 days of transfection, cells were lysed in 1 ml of a
lysis bu¡er (20 mM HEPES bu¡er pH 7.3, 150 mM NaCl, 0.5% NP-
40, 50 mM NaF, 1 mM phenylmethylsulfonyl £uoride and 1% apro-
tinin), then centrifuged. Cell extracts were incubated with 20 Wl (50%
FEBS 21722 18-3-99
0014-5793/99/$20.00 ß 1999 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 9 ) 0 0 2 5 4 - 9
*Corresponding author. Fax: (81) (942) 315 212.
E-mail: yosimura@isi.kurume-u.ac.jp
FEBS 21722 FEBS Letters 447 (1999) 5^9
v/v) of GST-RING ¢nger fusion protein bound to GSH-Sepharose,
then washed extensively with phosphate bu¡ered saline containing
0.5% NP-40, and analyzed by immunoblotting with anti-anti-Myc
(9E10) antibody as described [20].
For in vivo binding, MDM2 was co-expressed with MDMX or
MDMXvC in 293 cells, then immunoprecipitated with monoclonal
anti-MDM2 antibody (Santa Cruz Biotechnology). After 2 h incuba-
tion on ice, 20 Wl protein G-Sepharose was added to lysate and in-
cubated for a further 2 h. The beads were washed three times, then
subjected to immunoblotting with anti-Myc antibody.
2.3. Degradation assay
MDM2 was co-expressed with MDMX or vC-MDMX in 293 cells.
After 30 h transfection, 30 Wg/ml cycloheximide with or without 10
WM lactacystin [17] was added to the culture medium and cells were
further cultured for 0, 3, 6, or 12 h. After lysis, cell extracts were
subjected to 7% SDS-PAGE and immunoblotting with anti-Myc.
3. Results
3.1. Identi¢cation of MDMX as a MDM2-binding protein
To isolate MDM2-interacting protein, we screened several
yeast two hybrid libraries using MDM2 the N-terminal (1^
294) or C-terminal half (294^491) as baits (Fig. 1a). From
thymus cDNA library, we isolated six independent positive
clones of various lengths of MDMX genes by screening
with the C-terminal half but not with the N-terminal half.
One of the clones contained full length MDMX cDNA (Fig.
1a; CT-2) and the shortest one contained only 58 amino acids
including C-terminal RING ¢nger domain (codon 432^490)
(Fig. 1a; CT-34). Therefore, the C-terminal half of MDM2
that contains the Zinc ¢nger motif and the RING ¢nger motif
interacts with the RING ¢nger domain of MDMX.
We compared the strength of MDM2/MDMX interaction
by using yeast two-hybrid assay (Fig. 1b). The yeast strain
transfected with pBTM-MDMX (a bait containing the
LexA-binding domain BD) and pGAD-MDMX (a prey con-
taining Gal4-activation domain AD) did not grow without
histidine (His), indicating that MDMX did not form homo-
oligomer (Fig. 1b, A). On the other hand, the yeast strain
transfected with pBTM-MDM2 and pGAD-MDM2 grew
very slowly, suggesting that the two MDM2 molecules inter-
act weakly (Fig. 1b, C). However, MDMX and MDM2 inter-
acted more strongly (Fig. 1b, B and D). These data indicate
that MDMX and MDM2 preferentially form hetero-oligomer.
Similar results were obtained by quantitative L-galactosidase
assay (data not shown).
To identify the region of MDM2 that interacts with the
RING ¢nger domain of MDMX, several C-terminal regions
of MDM2 were examined for interaction with the MDMX
RING ¢nger domain using yeast two-hybrids (Fig. 2a). As
shown in Fig. 2b, the MDMX RING ¢nger domain, but
not the zinc ¢nger domain, did interact with the RING ¢nger
domain of MDM2 (Fig. 2b, C, G). The MDMX RING ¢nger
domain did not interact with the zinc ¢nger domain or the
internal domain of MDM2 (B,D). The MDMX Zinc ¢nger
domain did not interact with any regions of MDM2 (E^H).
These data indicate that MDM2 and MDMX forms hetero-
oligomer through their RING ¢nger domains.
3.2. Binding of MDMX with MDM2 in vitro and in vivo
To con¢rm the interaction between MDM2 and MDMX in
vitro and in vivo, we subcloned a Myc-epitope tagged version
of the full length MDM2 (Myc-MDM2) and full length
MDMX (Myc-MDMX) into mammalian expression vectors
and transiently transfected into 293 cells. The MDM2
RING ¢nger domain, MDM2 zinc ¢nger domain or
MDMX RING ¢nger domain were fused to GST and puri¢ed
from bacteria. These GST-fusion proteins immobilized on
GSH-Sepharose were incubated with cell extracts containing
Myc-MDM2 or Myc-MDMX (Fig. 3a). The MDM2-RING
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Fig. 1. MDM2 binds to the C-terminal region of MDMX. a: Struc-
ture of MDM2 used as bait and MDMX cDNA clones obtained by
yeast two hybrid screening from a human thymus cDNA library.
Positions (codon numbers) for p53 binding region, nuclear localiza-
tion signal (NLS), zinc ¢nger and RING ¢nger are shown. CT-34,
CT-29, CT-48, CT-1, CT-2 and CT-35 are clones obtained by
screening using MDM2 C-terminal region as bait. b: Growth of
L40 strain transfected with MDM2 and/or MDMX cDNAs either
in the presence (His) or absence (His3) of histidine. BD/AD indi-
cates the combination of binding domain (bait) and activation do-
main (prey). Yeast L40 was transfected with pBTM-MDMX (full
length) and pGAD-MDMX (A), pBTM-MDM2 (C-terminal half re-
gion) and pGAD-MDMX (B), pBTM-MDM2 and pGAD-MDM2
(C) or pBTM-MDMX and pGAD-MDM2 (D).
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¢nger domain (GST-2RING) but not the MDM2 zinc ¢nger
domain (GST-2Zinc) could capture Myc-MDM2 and Myc-
MDMX (lanes 5,6). The MDMX RING ¢nger domain
(GST-XRING) bound strongly to Myc-MDM2 (lane 12),
and weakly to Myc-MDMX (lane 11). Unlike the result of
the yeast two-hybrid assay, we detected relatively strong
homo-oligomeric interaction between GST-MDM2 RING
and Myc-MDM2 in vitro (lane 6). This may be due to the
very high concentration of GST-RING ¢nger domain in vitro.
MDMX lacking C-terminal RING ¢nger domain
(MDMXvC) did not bind to RING ¢nger domains of
MDM2 and MDMX (lanes 4,10).
Next we examined the hetero-oligomer formation of
MDM2 and MDMX in vivo. MDM2 was co-expressed with
either full length MDMX or MDMXvC in 293 cells, and
immunoprecipitated with an anti-MDM2 monoclonal anti-
body. As shown in Fig. 3b, Myc-MDMX was co-immunopre-
cipitated with anti-MDM2 (lane 11), while Myc-MDMXvC
was not co-precipitated (lane 12). The intensity of the MDMX
band co-precipitated with MDM2 was almost equal to that of
the MDM2 band, suggesting that the interaction between
MDM2 and MDMX is quite strong and stable. These data
indicate that MDMX interacts with MDM2 through its C-
terminal RING ¢nger domain in vivo as well as in vitro.
3.3. E¡ect of co-expression of MDMX on MDM2 stability
Since the MDM2 C-terminal region has been shown to
associate with ubiquitin-ligase activity, we examined ubiqui-
tin-proteasome dependent degradation of MDM2 in the pres-
ence or absence of MDMX. Stability of the proteins was
examined by immunoblotting after adding cycloheximide to
block new protein synthesis. As shown in Fig. 4a, Myc-
MDM2 was degraded with a half-life about 3^6 h. Degrada-
tion was almost completely abrogated by the proteasome in-
hibitor, lactacystin (Fig. 4b), con¢rming that the degradation
of MDM2 is dependent on proteasome [17]. The appearance
of the multiple higher molecular bands of MDM2 in the pres-
ence of proteasome inhibitor suggests the ubiquitination of
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Fig. 2. RING ¢nger domain interacts with MDMX RING ¢nger domain. a: cDNA fragments corresponding to the zinc ¢nger domain (Zinc),
internal domain (ID), and the RING ¢nger domain (RING) of MDM2 and MDMX were subcloned in pBTM (bait) or pGAD (prey). The
numbers indicate positions for subcloned regions. b: Growth of yeast L40 strains expressing indicated combinations of MDM2 and MDMX re-
gions cloned in pBTM/pGAD as in Fig. 1b, in the presence (His) or absence (His3) of histidine.
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the molecule [17]. In contrast, MDMX was a very stable pro-
tein. The protein level of MDMX was not much changed after
12 h of cycloheximide treatment (Fig. 4c). When full length
MDMX was co-expressed in MDM2, degradation of MDM2
was markedly suppressed (Fig. 4d). In contrast, Myc-
MDMXvC, which lacked a RING ¢nger domain and did
not interact with MDM2, could not a¡ect the half-life of
MDM2 (Fig. 4e). These data indicate that MDMX stabilizes
MDM2 by interacting with the MDM2 RING ¢nger domain.
4. Discussion
In this report, we demonstrated that MDMX hetero-oligo-
merizes with MDM2 through their RING ¢nger domains.
The RING ¢nger motif is a subgroup of the zinc ¢nger motif,
which was originally found to be involved in protein-DNA
interaction. However, more and more examples suggest that
the RING ¢nger domain is involved in protein-protein inter-
actions rather than protein-DNA interactions. For example,
the N-terminal RING ¢nger domain of BRCA-1, the heredi-
tary breast and ovarian cancer tumor suppresser gene, inter-
acts with BAP-1, a novel ubiquitin hydrolase that enhances
BRCA-1-mediated cell growth suppression [21]. The BRCA-1
RING ¢nger domain also binds to BARD-1, which also con-
tains a RING ¢nger motif in the N-terminus. Like MDM2
and MDMX, BRCA-1 and BARD-1 may hetero-oligomerize
through their RING ¢nger domains [22]. BARD-1 contains a
BRCT (BRCA1 C-terminus) domain similar to that of
BRCA-1, suggesting a role of BARD-1 in cell cycle regula-
tion. Although the meaning of hetero-oligomer formation be-
tween BARD-1 and BRCA-1 has not been clari¢ed, speci¢c
hetero-oligomeric interaction among two-related RING ¢nger
domains may be a common mechanism of hetero-oligomeri-
zation of the two related cell cycle regulator proteins.
MDM2 has been shown to promote degradation of p53.
The C-terminal RING ¢nger region of MDM2 has been sug-
gested as playing a role in the ubiquitin-proteasome depend-
ent degradation of p53 and MDM2 itself [23]. Honda et al.
demonstrated that MDM2 functions as a ubiquitin ligase E3
for P53 in vitro [15]. However, the molecular mechanism of
ubiquitination of MDM2 and p53 in vivo has not been clari-
¢ed yet. Interestingly, Zhang et al. reported that p19ARF binds
to the C-terminal region of MDM2 and promotes degradation
of MDM2, resulting in the stabilization of p53 [13]. Therefore,
MDMX seems to have a completely opposite e¡ect on
MDM2 degradation and probably on p53 stability. In addi-
tion, MDMX contains p53 binding motif at the N-terminus,
which can also potentially inactivate p53 [18,19]. We found
that MDMX synergistically inhibits transactivation activity of
p53 in cooperation with MDM2 (data not shown). These data
suggest that MDMX positively regulates MDM2 function for
p53 inactivation. It is of interest whether MDMX possesses
oncogenic activity like MDM2, which we are currently exam-
ining. Alternatively the MDM2-MDMX complex may play a
role in regulation of the cell cycle or apoptosis, which is in-
dependent of p53, since MDM2 has been shown to possess
both p53-dependent and independent functions [24,25].
MDM2 has been shown to be cleaved by CPP32-like pro-
tease during apoptosis [26,27]. This cleavage region is in the
internal region between the zinc ¢nger motif and the RING
¢nger motif, thus the cleaved product of MDM2 cannot in-
teract with MDMX. The meaning of this cleavage during
apoptosis is not clear at present. However, MDMX may be
involved in the regulation of MDM2 function during apopto-
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Fig. 3. MDM2 and MDMX interact through their RING ¢nger do-
mains in vitro (a) and in vivo (b). a: GST was fused with MDM2
RING ¢nger domain (GST-2RING), MDM2 zinc ¢nger domain
(GST-2Zinc) and MDMX RING ¢nger domain (GST-XRING) as
shown in Fig. 2a. Immobilized GST-fusion proteins on GSH-Seph-
arose were incubated with 293 cell extracts containing full length
Myc-MDM2, Myc-MDMX or C-terminal truncated MDMX (Myc-
MDMXvC). Bound proteins were analyzed by immunoblotting with
anti-Myc antibody. b: 293 cells were transfected with indicated com-
bination of plasmids carrying Myc-MDM2, Myc-MDMX or Myc-
MDMXvC. After 30 h, total cell lysates (TCL) or immunoprecipi-
tates with anti-MDM2 monoclonal antibody (IP: anti-MDM2) were
subjected to SDS-PAGE, followed by immunoblotting with anti-
Myc antibody. Positions for MDM2, MDMX and MDMXvC are
shown.
Fig. 4. The e¡ect of MDMX co-expression on MDM2 stability. 293
cells were transfected with plasmids carrying full length Myc-
MDM2 alone (a,b) or Myc-MDMX alone (c), or Myc-MDM2 with
full length MDMX (d) or with Myc-MDMXqC (e). After 30 h
transfection, 30 Wg/ml cycloheximide was added into the culture me-
dium (a^e). 10 WM lactacystin was also included in the culture me-
dium with cycloheximide in b. After indicated periods of incubation,
cells were lysed, then immunoblotting with anti-Myc antibody was
performed.
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sis. MDMX is highly expressed in the thymus. Therefore,
MDMX-MDM2 interaction may be involved in T cell devel-
opment by regulating p53-dependent or independent apopto-
sis.
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